Replies to post #114093 on Amarin Corp Plc (AMRN)

[sts66]

a handful or more of high prescribing doctors did not like what they saw happening to there patients biomarkers or worse yet events of some sort while on generic lovaza. So they switched there patients back to Lovaza

Interesting theory, but I'm not sure insurance would go along with it - docs would have to go to great lengths to show patients are being harmed by GL and need L to get them to pay for brand name at a much higher cost.

The board has discussed this before that generic lovaza is garbage.

Not sure I recall reading that, except maybe that people were reporting more GI problems with it - but I do remember when I was looking for 2017 Part D coverage I saw full retail price for GL was only $93 and thought "how the heck are they making any money selling GL at what appears to be cost to produce it?". Assuming they (Teva?) *are* making a profit at that price point, means their cost may be as low as the $60's if gross margins are similar to AMRN's margins on V - and I cannot believe you can make 4 g/day of Rx fish oil at that price w/o cutting corners somewhere.


P.S. Had major problems with my computer and browser the last 1 1/2 days, have fallen 200+ posts behind, so forgive me for being late to the party.